Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1754)	2/20/2007 4:24:15 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Ian, The BTK needs to close above the R from the Feb 8-Feb 9 Hs at the 786- 787 level before it can tackle the Jan 19 & Nov 17 Hs at 789 <g> Its more recent Ls were above the Jan 26 L of 759, which in turn was above the Dec22 Jan 2 Ls of 742, but it remains on a nearterm DT until it can close above 786 <g> bigcharts.marketwatch.com RAGL Bernard

To: Ian@SI who wrote (1754)	10/5/2007 11:39:10 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GENZ Seems ready to continue the upmove that started Monday. bigcharts.marketwatch.com It received approval in Japan to market its Elaprase for HS bizjournals.com Genzyme gets approval in Japan for Elaprase Friday October 5, 11:15 am ET Genzyme Corp. said Friday it has received approval to market Elaprase in Japan for the treatment of Hunter syndrome. Cambridge, Mass.-based Genzyme said Elaprase, which is also known as idursulfase, is an enzyme replacement therapy developed by Shire Human Genetic Therapies Inc., and Genzyme is commercializing the product in Japan and other Asia Pacific countries under an agreement with Shire. Genzyme intends to launch Elaprase this quarter, following reimbursement approval, the firm said in a statement. Under its agreement with Shire, Genzyme will record product sales in the region and allocate approximately one-third of net sales to Shire. Genzyme will make a $3 million milestone payment to Shire in recognition of Japanese marketing approval, and it will make a $4 million milestone payment upon reimbursement approval. Hunter syndrome, also known as Mucopolysaccharidosis II, is a rare, life-threatening genetic condition mainly affecting males that results from the absence or insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. Without this enzyme, cellular waste products accumulate in tissues and organs which then begin to malfunction, leading to severe clinical complications and early mortality. Elaprase is the fifth enzyme replacement therapy that Genzyme has introduced in Japan. Genzyme officials said the firm is currently working to obtain marketing approval for Elaprase in several additional countries. The company anticipates approval in Australia by the end of this year and in Taiwan and South Korea next year. Snip GENZ has 4Qs of better revenues & earnings. The EE for 2007 are around $3.40 vs. the $2.77 in 2006 & for 2008 another 15% in earnings is expected. The stock needs to get over its Nov 2005 H of 77.82 in order to make an all time H. bigcharts.marketwatch.com Bernard

To: Ian@SI who wrote (1754)	10/8/2007 9:38:40 AM
From: Jibacoa	Respond to of 3722

IVGN Closed its Aug 2 UG & seems ready to go over its Sep H.<g> bigcharts.marketwatch.com It had some positive announcements about its STEMPRO EZChek Invitrogen Introduces Multiplex Kit for Stem Cells Monday October 8, 8:00 am ET First-of-Its-Kind Kit Allows for Rapid and Reliable Monitoring of Differentiation CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN - News), a provider of essential life science technologies for research, production and diagnostics, today announced the launch of a new kit that allows researchers to quickly and reliably monitor the state of human embryonic stem cells (hESCs). The STEMPRO® EZChek(TM) Multiplex PCR Kit allows scientists to monitor hESCs with one reaction, using fewer sample cells than ever before. The most important characteristic of ESCs is their pluripotency, or ability to differentiate into all three primitive cell lineages in the body -- endoderm, ectoderm and mesoderm. Researchers working with hESCs must continually screen them to ascertain pluripotency. A preferred monitoring method is the use of polymerase chain reaction (PCR) to amplify specific markers associated with pluripotency. PCR is a sensitive and early measurement of differentiation, but it requires the researcher to sacrifice sample cells, leaving fewer behind for research purposes. The STEMPRO® EZChek(TM) Kit allows for the analysis of four early differentiation markers using a small sample and a single-tube reaction. Without the kit, researchers need to carry out five separate reactions in five tubes, using many more cells. In addition, the kit requires no extensive additional training to achieve desired results. "The crux of any stem cell researcher's work is the ability to monitor the differentiation state of hESCs," said Joydeep Goswami, Vice President, Stem Cells and Regenerative Medicine. "Unfortunately, current processes are laborious and consume more cells, a precious scientific resource. STEMPRO® EZChek(TM) makes this important step less time-consuming and less costly and allows researchers to assess whether the cells remain pluripotent or have differentiated into endoderm, ectoderm or mesoderm lineages." Invitrogen is the premier supplier of tools and reagents for stem cell research. The company offers more than 1,200 products tailored to various parts of the stem cell research workflow for embryonic and adult stem cell populations, including Dynabeads® for cell separation; pre-conjugated stem cell antibodies from Molecular Probes; and gold standard media from GIBCO such as KNOCKOUT(TM) Serum Replacement and MesenPRO(TM) RS reduced serum medium for mesenchymal stem cells. The company recently announced the launch of STEMPRO® hESC SFM, a new fully-defined, serum-and feeder-free media specifically formulated for the growth and expansion of hESCs, and the STEMPRO® EZPassage(TM) tool for stem cell passaging. Snip After going over its Sep H the next resistance would be its Jul 2005 H at 88.50 bigcharts.marketwatch.com Bernard

To: Ian@SI who wrote (1754)	1/25/2008 10:58:14 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AMGN opened with an UG & was up 4.38% on volume of 24,854,415 > 2x its ADV, it closed above $48 & continued to do OK AHs. bigcharts.marketwatch.com It announced yesterday after the market closed, the results of a double-blind study comparing denosumab given by subcutaneous injections 2x Yr. vs. oral doses of FOSAMAX given 1x week, on bone density in postmenopausal women.It said that the study met its primary & all its secondary endpoints. The drug showed greater bone density gains at the hip & distal radius than Fosamax.The primary endpoint was the magnitude of bone density improvement at the hip, which was approximately 40% greater than in the Fosamax group. The incidence of side effects were similar in both groups, which involved a total of 1,189 women with postmenopausal osteoporosis. Analyst have a target for AMGN around $60 but the stock still needs to close its Dec10 DG. bigcharts.marketwatch.com AMGB Trades around 2.65xBV with a +CF around $4.80 It has had better earnings in its last 4Qs in spiet of lower revenues in the last 2Qs. The EE for 2008 are for further improvement to around $4.40/shr & for 2009 to around $4.80/shr The short ratio came down almost 20% in the last month & still is around 2x its ADV. If it can close its Dec 10 DG, it seems the stock should be able to test the resistance from its June-Oct H at the 59 level. bigcharts.marketwatch.com On a close above $60, the stock will start getting off from its long term DT coming from its Sep 2005 at the $86.92 level bigcharts.marketwatch.com Bernard